Infectious disease experts from Asia reviewed data from the VIEW-hub database on vaccine use and impact, developed by John Hopkins Bloomberg School of Public Health and the International Vaccine Access Center. The findings from the study were reported by Expert Review of Vaccines.
The findings shows that Vaxzevria and the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines offer an ‘equivalent degree’ of protection against hospitalisation (91-93%) and death (91-93%) following two doses, regardless of age.
